| Autor: |
Joudinaud, Romane, Boudry, Augustin, Fenwarth, Laurène, Geffroy, Sandrine, Salson, Mikaël, Dombret, Herve, Berthon, Céline, Pigneux, Arnaud, Lebon, Delphine, Haddaoui, Lamya, Itzykson, Raphael, Recher, Christian, Bidet, Audrey, Delabesse, Eric, Hunault, Mathilde, Preudhomme, Claude, Duployez, Nicolas, Dumas, Pierre-Yves |
| Zdroj: |
Blood; November 2023, Vol. 142 Issue: 1, Number 1 Supplement 1 p976-976, 1p |
| Abstrakt: |
Introduction:Despite the wider use of midostaurin (MIDO) in combination with intensive chemotherapy (ICT) as the 1st-line treatment for FLT3-mutated acute myeloid leukemia (AML), complete remission (CR) rates are close to 60%, and relapses occur in over 40% of cases, demonstrating the ability of leukemic cells to resist and evade therapy ( Stone et al., NEJM 2017). Conventional fragment-length analyses of paired diagnosis/relapse samples have shown that FLT3-internal tandem duplications (ITDs) are retained in 80% and 50% of cases following ICT alone and MIDO+ICT respectively ( Schmalbrock et al., Blood 2021). Only limited data are available on the dynamics of FLT3-ITDs or other co-mutations in refractory patients (pts). Here, we conducted a retrospective study involving 115 pts with relapsed/refractory AML harboring FLT3-ITD at diagnosis. |
| Databáze: |
Supplemental Index |
| Externí odkaz: |
|
